MFDS Approves HYUNDAI BIOSCIENCE CO., LTD.’s ‘Penitrium’ Ten Days After Seoul National University Hospital’s Request… Paving the Way for Follow-Up Treatment
First Patient in the Lowest-Dose Group of Phase 1 Trial for Castration-Resistant Prostate Cancer Begins Extended Treatment
New Oral Drug Targets Tumor Microenvironment Barriers… Full Efforts Focused on Timely Supply and Safety Monitoring
[Edaily Reporter YU JIN-HEE ] #HYUNDAI BIOSCIENCE CO., LTD.’s oral anticancer drug candidate “Penitrium” (CP-PCA07) has obtained approval for use in a specific therapeutic context for the first patient enrolled in a domestic prostate cancer clinical trial and will now proceed to extended administration.
HYUNDAI BIOSCIENCE CO., LTD. announced on the 17th that it had received approval from the Ministry of Food and Drug Safety for the individualized use of Penitrium for therapeutic purposes for the first patient enrolled in the Phase 1 clinical trial (ADM-PC-001) for castration-resistant prostate cancer currently underway at Seoul National University Hospital.
(Photo: HYUNDAI BIOSCIENCE CO., LTD.)
This approval applies to patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed following prior hormone therapy. The patient in question was assigned to the lowest-dose group in the Phase 1 clinical trial starting last August and received a combination of 600 mg of Penitrium per day (200 mg three times daily) and the standard treatment, enzalutamide.
On the 1st, following the completion of the planned 12-week official treatment schedule, the patient’s attending physician, Professor Chang-wook Jeong of the Department of Urology at Seoul National University Hospital, submitted an application for approval for use in therapeutic trials to the Ministry of Food and Drug Safety (MFDS) on the 6th. This decision was based on a comprehensive assessment of the patient’s general condition and tolerability—which made it difficult to administer cytotoxic chemotherapy such as docetaxel—as well as the treatment response observed during the preceding 12-week combination therapy.
With the MFDS granting approval just ten days after receiving the application, the potential treatment gap following the completion of the clinical trial has been minimized, and follow-up treatment can now continue for six months by adding Penitrium to the existing enzalutamide regimen.
HYUNDAI BIOSCIENCE CO., LTD. will provide a 180-day supply of Penitrium (a total of 1,080 tablets) free of charge based on a Letter of Intent issued at the request of the attending physician. The company plans to ensure timely supply of the medication through cooperation with medical institutions, while also supporting regular monitoring and reporting procedures regarding disease progression and safety. The actual duration of treatment will be determined based on the patient’s condition and the clinical judgment of the medical team.
Penitrium is a new drug candidate designed to overcome “pseudo-resistance”—a condition in which existing anticancer drugs fail to work effectively due to physical barriers in the tumor microenvironment formed by cancer-associated fibroblasts (CAFs) and the extracellular matrix (ECM). Currently, a Phase 1 clinical trial is underway in South Korea to evaluate the safety, tolerability, and efficacy of Penitrium in combination with standard therapies in patients with castration-resistant prostate cancer through a stepwise dose-escalation protocol. Additionally, in September, the company received a “Study May Proceed” approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a clinical trial for patients with recurrent or refractory advanced solid tumors.
Jin Geun-woo, CEO of HYUNDAI BIOSCIENCE CO., LTD., stated, “We are grateful to the Ministry of Food and Drug Safety for its prompt review, which ensures that patient treatment can continue without interruption.” He added, “We will work closely with healthcare professionals to ensure timely drug supply and meticulous safety monitoring, and we will continue to thoroughly demonstrate the safety and efficacy of this combination therapy in our ongoing Phase 1 clinical trial for prostate cancer in Korea.”
Tension is mounting in the domestic credit market following the U.S. Federal Reserve’s decision last September to raise the benchmark interest rate for the first time in three years and two months. As…
#HYUNDAI BIOSCIENCE CO., LTD.’s oral anticancer drug candidate “Penitrium” (CP-PCA07) has obtained approval for use in a specific therapeutic context for the first patient enrolled in a domestic prost…
“Herjumma,” a treatment for breast and stomach cancer. (Active ingredient: trastuzumab) (Photo: Celltrion)
Celltrion(068270)has secured a large-scale supply contract for “Herjumma” (active ingredi…